BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 19179556)

  • 1. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.
    Posner MR; Norris CM; Wirth LJ; Shin DM; Cullen KJ; Winquist EW; Blajman CR; Mickiewicz EA; Frenette GP; Plinar LF; Cohen RB; Steinbrenner LM; Freue JM; Gorbunova VA; Tjulandin SA; Raez LE; Adkins DR; Tishler RB; Roessner MR; Haddad RI;
    Ann Oncol; 2009 May; 20(5):921-7. PubMed ID: 19179556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
    Janoray G; Pointreau Y; Garaud P; Chapet S; Alfonsi M; Sire C; Jadaud E; Calais G
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26681800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.
    Pointreau Y; Garaud P; Chapet S; Sire C; Tuchais C; Tortochaux J; Faivre S; Guerrif S; Alfonsi M; Calais G
    J Natl Cancer Inst; 2009 Apr; 101(7):498-506. PubMed ID: 19318632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II.
    Dietz A; Wichmann G; Kuhnt T; Pfreundner L; Hagen R; Scheich M; Kölbl O; Hautmann MG; Strutz J; Schreiber F; Bockmühl U; Schilling V; Feyer P; de Wit M; Maschmeyer G; Jungehülsing M; Schroeder U; Wollenberg B; Sittel C; Münter M; Lenarz T; Klussmann JP; Guntinas-Lichius O; Rudack C; Eich HT; Foerg T; Preyer S; Westhofen M; Welkoborsky HJ; Esser D; Thurnher D; Remmert S; Sudhoff H; Görner M; Bünzel J; Budach V; Held S; Knödler M; Lordick F; Wiegand S; Vogel K; Boehm A; Flentje M; Keilholz U
    Ann Oncol; 2018 Oct; 29(10):2105-2114. PubMed ID: 30412221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial.
    Janoray G; Pointreau Y; Alfonsi M; Sire C; Geoffrois L; de Raucourt D; Bardet E; Calais MH; Garaud P; Calais G
    Eur J Cancer; 2020 Jul; 133():86-93. PubMed ID: 32454417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
    Lorch JH; Goloubeva O; Haddad RI; Cullen K; Sarlis N; Tishler R; Tan M; Fasciano J; Sammartino DE; Posner MR;
    Lancet Oncol; 2011 Feb; 12(2):153-9. PubMed ID: 21233014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laryngeal preservation by induction chemotherapy plus radiotherapy in locally advanced head and neck cancer: the M. D. Anderson Cancer Center experience.
    Shirinian MH; Weber RS; Lippman SM; Dimery IW; Earley CL; Garden AS; Michaelson J; Morrison WH; Kramer A; Byers R
    Head Neck; 1994; 16(1):39-44. PubMed ID: 7510276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
    Hitt R; Iglesias L; López-Pousa A; Berrocal-Jaime A; Grau JJ; García-Girón C; Martínez-Trufero J; Guix M; Lambea-Sorrosal J; Del Barco-Morillo E; León-Vintró X; Cunquero-Tomas AJ; Baste N; Ocaña A; Cruz-Hernández JJ;
    Clin Transl Oncol; 2021 Apr; 23(4):764-772. PubMed ID: 32797376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential four-drug chemotherapy and intensity-modulated radiotherapy for larynx preservation in resectable advanced larynx and hypopharynx cancer: A pilot study.
    Su X; He C; Tang T; Chen W; Li Z; Chen Y; Yang A
    Am J Otolaryngol; 2017; 38(1):52-56. PubMed ID: 27825651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study.
    Mesía R; Garcia-Saenz JA; Lozano A; Pastor M; Grau JJ; Martínez-Trufero J; Lambeaz J; Martínez-Galán J; Mel JR; González B; Vázquez S; Mañós M; Taberna M; Cirauqui B; Del Barco E; Casado E; Rubió-Casadevall J; Rodríguez-Jaráiz A; Cruz JJ;
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):473-480. PubMed ID: 28011050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.
    Forastiere AA; Zhang Q; Weber RS; Maor MH; Goepfert H; Pajak TF; Morrison W; Glisson B; Trotti A; Ridge JA; Thorstad W; Wagner H; Ensley JF; Cooper JS
    J Clin Oncol; 2013 Mar; 31(7):845-52. PubMed ID: 23182993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction chemotherapy before chemoradiotherapy in locally advanced head and neck cancer: the future?
    Paccagnella A; Mastromauro C; D'Amanzo P; Ghi MG
    Oncologist; 2010; 15 Suppl 3():8-12. PubMed ID: 21036883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients.
    Altundag O; Gullu I; Altundag K; Yalcin S; Ozyar E; Cengiz M; Akyol F; Yucel T; Hosal S; Sozeri B
    Head Neck; 2005 Jan; 27(1):15-21. PubMed ID: 15515158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility, toxicity, and efficacy of short induction chemotherapy of docetaxel plus cisplatin or carboplatin (TP) followed by concurrent chemoradio-therapy for organ preservation in advanced cancer of the hypopharynx, larynx, and base of tongue. Early results.
    Semrau S; Waldfahrer F; Lell M; Linke R; Klautke G; Kuwert T; Uder M; Iro H; Fietkau R
    Strahlenther Onkol; 2011 Jan; 187(1):15-22. PubMed ID: 21234526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: Outcome prediction after one cycle induction chemotherapy by a score based on clinical evaluation, computed tomography-based volumetry and
    Wichmann G; Krüger A; Boehm A; Kolb M; Hofer M; Fischer M; Müller S; Purz S; Stumpp P; Sabri O; Dietz A; Kluge R
    Eur J Cancer; 2017 Feb; 72():144-155. PubMed ID: 28033526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
    Posner MR; Hershock DM; Blajman CR; Mickiewicz E; Winquist E; Gorbounova V; Tjulandin S; Shin DM; Cullen K; Ervin TJ; Murphy BA; Raez LE; Cohen RB; Spaulding M; Tishler RB; Roth B; Viroglio Rdel C; Venkatesan V; Romanov I; Agarwala S; Harter KW; Dugan M; Cmelak A; Markoe AM; Read PW; Steinbrenner L; Colevas AD; Norris CM; Haddad RI;
    N Engl J Med; 2007 Oct; 357(17):1705-15. PubMed ID: 17960013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
    Vermorken JB; Remenar E; van Herpen C; Gorlia T; Mesia R; Degardin M; Stewart JS; Jelic S; Betka J; Preiss JH; van den Weyngaert D; Awada A; Cupissol D; Kienzer HR; Rey A; Desaunois I; Bernier J; Lefebvre JL;
    N Engl J Med; 2007 Oct; 357(17):1695-704. PubMed ID: 17960012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II organ-preservation trial: Concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy.
    Popovtzer A; Burnstein H; Stemmer S; Limon D; Hili O; Bachar G; Sopov V; Feinmesser R; Groshar D; Shvero J
    Head Neck; 2017 Feb; 39(2):227-233. PubMed ID: 27556178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
    Hitt R; Grau JJ; López-Pousa A; Berrocal A; García-Girón C; Irigoyen A; Sastre J; Martínez-Trufero J; Brandariz Castelo JA; Verger E; Cruz-Hernández JJ;
    Ann Oncol; 2014 Jan; 25(1):216-25. PubMed ID: 24256848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
    Teo M; Karakaya E; Young CA; Dyker KE; Coyle C; Sen M; Prestwich RJ
    Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):647-53. PubMed ID: 23948462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.